Mirati Therapeutics Inc.

01/21/2022 | Press release | Distributed by Public on 01/21/2022 09:04

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers